Adam M. Spivak,
MD
Languages Spoken: English
Dr. Spivak joined the Division of Infectious Diseases at the University of Utah in the fall of 2011 after completing residency and fellowship training at Johns Hopkins University School of Medicine in Baltimore, Maryland. He cares for HIV patients as a member of the Clinic 1A staff and attends on the inpatient Infectious Diseases consult service at the University of Utah Hospital. Dr. Spivak teaches in the medical school, conducts translational research on HIV persistence and eradication, and is a co-founder and leader of Utah's first and only free HIV prevention clinic.
Clinical Locations
Infectious Diseases, Area E
801-585-2031
Specialties
Board Certification and Academic Information
| Academic Departments | Internal Medicine
-
Assistant Professor Pathology - Adjunct Assistant Professor |
| Academic Divisions | Infectious Diseases Microbiology and Immunology |
| Board Certification | American Board of Internal Medicine (Internal Medicine) American Board of Internal Medicine (Sub: Infectious Disease) |
Patient Rating
The Patient Rating score is an average of all responses to care provider related questions on our nationally-recognized Press Ganey Patient Satisfaction Survey.
Responses are measured on a scale of 1 to 5 with 5 being the best score.
Likelihood of recommending care provider
5.0/ 5
Care provider's explanation of condition/problem
4.9/ 5
Care provider's effort to include me in decisions
4.9/ 5
Wait time at clinic
4.6/ 5
Care provider's concern for questions & worries
4.9/ 5
Patient Comments
Patient comments are gathered from our Press Ganey Patient Satisfaction Survery and displayed in their entirety. Patients are de-identified for confidentiality and patient privacy.
UofU Patient
June 24, 2021
UH HOSPITALS AND CLINICS
great doctor
UofU Patient
February 28, 2021
UH HOSPITALS AND CLINICS
Care provider is always on quest for the best solution for me.
UofU Patient
February 28, 2021
UH HOSPITALS AND CLINICS
Dr Adam Spivak is just phenomenal
UofU Patient
January 27, 2021
UH HOSPITALS AND CLINICS
Dr. Spivak was thorough and kind. He listened to me and was empathetic and compassionate. I would highly recommend him.
UofU Patient
December 13, 2020
UH HOSPITALS AND CLINICS
DR Adam Spivak and his other attending staff are highly recommended by me to give great care & help
UofU Patient
November 25, 2020
UH HOSPITALS AND CLINICS
Dr Adam Spivak and the rest of his accompanying staff are amazing
UofU Patient
October 26, 2020
UH HOSPITALS AND CLINICS
borh dr Spivak and Christine e so kind and caring
UofU Patient
October 24, 2020
UH HOSPITALS AND CLINICS
I feel extremely confident in the care I get through Clinic 1A - this includes the doctors, nurses, pharmacy team, advocates and front desk check-in personnel.
UofU Patient
October 06, 2020
UH HOSPITALS AND CLINICS
Dr Adam Spivak is phenomenal
UofU Patient
October 01, 2020
UH HOSPITALS AND CLINICS
Dr Adam Spivak is phenomenal, I'm so grateful that he is caring for me in my health conditions
UofU Patient
September 20, 2020
UH HOSPITALS AND CLINICS
I trust all the medical professionals at the Infectious disease clinic. I always feel they are invested in seeing that I get the best health outcome possible.
UofU Patient
April 07, 2020
UH HOSPITALS AND CLINICS
I loved Dr. Spivak (or however you spell his name). He is very friendly and likes to talk (in a good way).
UofU Patient
March 24, 2020
UH HOSPITALS AND CLINICS
Dr. Spivak was incredible and super friendly.He was incredibly informative and made sure I understood everything that was going on.
UofU Patient
February 18, 2020
UH HOSPITALS AND CLINICS
with the student doctor I dont feel like Im being heard and she talks down to me. Then she reports to Dr Spivak but by the time he gets involve Im ready to leave.
Dr. Spivak joined the Division of Infectious Diseases at the University of Utah in the fall of 2011 after completing residency and fellowship training at Johns Hopkins University School of Medicine in Baltimore, Maryland. He cares for HIV patients as a member of the Clinic 1A staff and attends on the inpatient Infectious Diseases consult service at the University of Utah Hospital. Dr. Spivak teaches in the medical school, conducts translational research on HIV persistence and eradication, and is a co-founder and leader of Utah's first and only free HIV prevention clinic.
Academic Locations
School of Medicine
801-587-1964
Board Certification and Academic Information
| Academic Departments | Internal Medicine
-
Assistant Professor Pathology - Adjunct Assistant Professor |
| Academic Divisions | Infectious Diseases Microbiology and Immunology |
| Board Certification | American Board of Internal Medicine (Internal Medicine) American Board of Internal Medicine (Sub: Infectious Disease) |
Education History
| Fellowship | Johns Hopkins University School of Medicine Infectious Diseases Fellow, 2011 |
| Chief Resident | Johns Hopkins University School of Medicine Internal Medicine Chief Resident, 2007 |
| Residency | Johns Hopkins University School of Medicine Internal Medicine Resident, 2005 |
| Internship | Johns Hopkins University School of Medicine Internal Medicine Intern, 2003 |
| Professional Medical | University of Maryland School of Medicine Medicine M.D., 2002 |
| Undergraduate | Princeton University English Literature A.B., 1997 |
Selected Publications - Journal Articles
Journal Article
- Sarabia I, Novis CL, Macedo AB, Takata H, Nell R, Kakazu JC, Furler RL, Shakya B, Schubert HL, Hill CP, DePaula-Silva AB, Spivak AM, Trautmann L, Planelles V, Bosque A (2021). Activation of the Anti-Oxidative Stress Response Reactivates Latent HIV-1 Through the Mitochondrial Antiviral Signaling Protein Isoform MiniMAVS. Front Immunol, 12, 682182.
- Trivedi S, Afroz T, Bennett MS, Angell K, Barros F, Nell RA, Ying J, Spivak AM, Leung DT (2021). Diverse Mucosal-Associated Invariant TCR Usage in HIV Infection. Immunohorizons, 5(5), 360-369.
- Gibson EG, Pender M, Angerbauer M, Cook C, Jones B, Spivak AM, Spivak ES, Swaminathan S (2021). Prolonged SARS-CoV-2 Illness in a Patient Receiving Ocrelizumab for Multiple Sclerosis. Open Forum Infect Dis, 8(7), ofab176.
- Zheng Y, Larragoite ET, Williams ESCP, Lama J, Cisneros I, Delgado JC, Slev P, Rychert J, Innis EA, Coiras M, Rondina MT, Spivak AM, Planelles V (2021). Neutralization assay with SARS-CoV-1 and SARS-CoV-2 spike pseudotyped murine leukemia virions. Virol J, 18(1), 1.
- Schynkel T, Szaniawski MA, Spivak AM, Bosque A, Planelles V, Vandekerckhove L, Trypsteen W (2020). Interferon-Mediated Long Non-Coding RNA Response in Macrophages in the Context of HIV. Int J Mol Sci, 21(20).
- Luetkens T, Metcalf R, Planelles V, Zheng Y, Larragoite ET, Spivak ES, Spivak AM, Steinbach M, Blaylock RC, Avila SV, Hankey KG, Martins TB, Slev PR, Mannuel HD, Sajadi M, Rapoport AP, Atanackovic D (2020). Successful transfer of anti-SARS-CoV-2 immunity using convalescent plasma in an MM patient with hypogammaglobulinemia and COVID-19. Blood Adv, 4(19), 4864-4868.
- Abdel-Mohsen M, Richman D, Siliciano RF, Nussenzweig MC, Howell BJ, Martinez-Picado J, Chomont N, Bar KJ, Yu XG, Lichterfeld M, Alcami J, Hazuda D, Bushman F, Siliciano JD, Betts MR, Spivak AM, Planelles V, Hahn BH, Smith DM, Ho YC, Buzon MJ, Gaebler C, Paiardini M, Li Q, Estes JD, Hope TJ, Kostman J, Mounzer K, Caskey M, Fox L, Frank I, Riley JL, Tebas P, Montaner LJ, BEAT-HIV Delaney Collaboratory to Cure HIV-1 infection (2020). Recommendations for measuring HIV reservoir size in cure-directed clinical trials. Nat Med, 26(9), 1339-1350.
- Sorensen ES, Macedo AB, Resop RS, Howard JN, Nell R, Sarabia I, Newman D, Ren Y, Jones RB, Planelles V, Spivak AM, Bosque A (2020). Structure-Activity Relationship Analysis of Benzotriazine Analogues as HIV-1 Latency-Reversing Agents. Antimicrob Agents Chemother, 64(8).
- Pache L, Marsden MD, Teriete P, Portillo AJ, Heimann D, Kim JT, Soliman MSA, Dimapasoc M, Carmona C, Celeridad M, Spivak AM, Planelles V, Cosford NDP, Zack JA, Chanda SK (2020). Pharmacological Activation of Non-canonical NF-κB Signaling Activates Latent HIV-1 Reservoirs In Vivo. Cell Rep Med, 1(3), 100037.
- Szaniawski MA, Spivak AM (2020). Senotherapeutics and HIV-1 Persistence. Current HIV - AIDS Reports, 17(3), 219-225.
- Pan F, Xiao X, Guo J, Song Y, Li H, Patel DP, Spivak AM, Alukal JP, Zhang X, Xiong C, Li PS, Hotaling JM (2020). No evidence of severe acute respiratory syndrome-coronavirus 2 in semen of males recovering from coronavirus disease 2019. Fertil Steril, 113(6), 1135-1139.
- Szaniawski MA, Spivak AM (2019). Senotherapeutics for HIV and aging. Curr Opin HIV AIDS, 15(2), 83-93.
- Larragoite ET, Spivak AM (2019). Down but not out. eLife, 8.
- Rodrguez-Mora S, Spivak AM, Szaniawski MA, Lpez-Huertas MR, Alcam J, Planelles V, Coiras M (2019). Tyrosine Kinase Inhibition: a New Perspective in the Fight against HIV. Current HIV - AIDS Reports, 16(5), 414-422.
- Szaniawski MA, Spivak AM, Bosque A, Planelles V (2018). Sex Influences SAMHD1 Activity and Susceptibility to Human Immunodeficiency Virus-1 in Primary Human Macrophages. J Infect Dis, 219(5), 777-785.
- Reeves DB, Duke ER, Wagner TA, Palmer SE, Spivak AM, Schiffer JT (2018). A majority of HIV persistence during antiretroviral therapy is due to infected cell proliferation. Nat Commun, 9(1), 4811.
- Spivak AM, Nell RA, Petersen M, Martins L, Sebahar P, Looper RE, Planelles V (2018). Synthetic Ingenols Maximize Protein Kinase C-Induced HIV-1 Latency Reversal. Antimicrob Agents Chemother, 62(11).
- Macedo AB, Novis CL, De Assis CM, Sorensen ES, Moszczynski P, Huang SH, Ren Y, Spivak AM, Jones RB, Planelles V, Bosque A (2018). Dual TLR2 and TLR7 agonists as HIV latency-reversing agents. JCI Insight, 3(19).
- Macedo AB, Resop RS, Martins LJ, Szaniawski MA, Sorensen ES, Spivak AM, Nixon DF, Jones RB, Planelles V, Bosque A (2018). Influence of Biological Sex, Age, and HIV Status in an In Vitro Primary Cell Model of HIV Latency Using a CXCR4 Tropic Virus. AIDS Res Hum Retroviruses, 34(9), 769-777.
- Szaniawski MA, Spivak AM, Cox JE, Catrow JL, Hanley T, Williams ESCP, Tremblay MJ, Bosque A, Planelles V (2018). SAMHD1 Phosphorylation Coordinates the Anti-HIV-1 Response by Diverse Interferons and Tyrosine Kinase Inhibition. mBio, 9(3).
- Abdel-Mohsen M, Kuri-Cervantes L, Grau-Exposito J, Spivak AM, Nell RA, Tomescu C, Vadrevu SK, Giron LB, Serra-Peinado C, Genesc M, Castellv J, Wu G, Del Rio Estrada PM, Gonzlez-Navarro M, Lynn K, King CT, Vemula S, Cox K, Wan Y, Li Q, Mounzer K, Kostman J, Frank I, Paiardini M, Hazuda D, Reyes-Tern G, Richman D, Howell B, Tebas P, Martinez-Picado J, Planelles V, Buzon MJ, Betts MR, Montaner LJ (2018). CD32 is expressed on cells with transcriptionally active HIV but does not enrich for HIV DNA in resting T cells. Sci Transl Med, 10(437).
- Spivak AM, Planelles V (2018). Novel Latency Reversal Agents for HIV-1 Cure. Annu Rev Med, 69, 421-436.
- Bosque A, Nilson KA, Macedo AB, Spivak AM, Archin NM, Van Wagoner RM, Martins LJ, Novis CL, Szaniawski MA, Ireland CM, Margolis DM, Price DH, Planelles V (2017). Benzotriazoles Reactivate Latent HIV-1 through Inactivation of STAT5 SUMOylation. Cell Rep, 18(5), 1324-1334.
- Spivak AM, Larragoite ET, Coletti ML, Macedo AB, Martins LJ, Bosque A, Planelles V (2016). Janus kinase inhibition suppresses PKC-induced cytokine release without affecting HIV-1 latency reversal ex vivo. Retrovirology, 13(1), 88.
- Garrido C, Spivak AM, Soriano-Sarabia N, Checkley MA, Barker E, Karn J, Planelles V, Margolis DM (2016). HIV Latency-Reversing Agents Have Diverse Effects on Natural Killer Cell Function. Front Immunol, 7, 356.
- Martins LJ, Bonczkowski P, Spivak AM, De Spiegelaere W, Novis CL, DePaula-Silva AB, Malatinkova E, Trypsteen W, Bosque A, Vanderkerckhove L, Planelles V (2016). Modeling HIV-1 Latency in Primary T Cells Using a Replication-Competent Virus. AIDS Res Hum Retroviruses, 32(2), 187-93.
- Spivak AM, Planelles V (2016). HIV-1 Eradication: Early Trials (and Tribulations). Trends Mol Med, 22(1), 10-27.
- Spivak AM, Bosque A, Balch AH, Smyth D, Martins L, Planelles V (2015). Ex Vivo Bioactivity and HIV-1 Latency Reversal by Ingenol Dibenzoate and Panobinostat in Resting CD4(+) T Cells from Aviremic Patients. Antimicrob Agents Chemother, 59(10), 5984-91.
- Pache L, Dutra MS, Spivak AM, Marlett JM, Murry JP, Hwang Y, Maestre AM, Manganaro L, Vamos M, Teriete P, Martins LJ, Knig R, Simon V, Bosque A, Fernandez-Sesma A, Cosford ND, Bushman FD, Young JA, Planelles V, Chanda SK (2015). BIRC2/cIAP1 Is a Negative Regulator of HIV-1 Transcription and Can Be Targeted by Smac Mimetics to Promote Reversal of Viral Latency. Cell Host Microbe, 18(3), 345-53.
- Spivak AM, Andrade A, Eisele E, Hoh R, Bacchetti P, Bumpus NN, Emad F, Buckheit R 3rd, McCance-Katz EF, Lai J, Kennedy M, Chander G, Siliciano RF, Siliciano JD, Deeks SG (2014). A pilot study assessing the safety and latency-reversing activity of disulfiram in HIV-1-infected adults on antiretroviral therapy. Clin Infect Dis, 58(6), 883-90.
- Barber AE, Norton JP, Spivak AM, Mulvey MA (2013). Urinary tract infections: current and emerging management strategies. Clin Infect Dis, 57(5), 719-24.
- Weil AF, Ghosh D, Zhou Y, Seiple L, McMahon MA, Spivak AM, Siliciano RF, Stivers JT (2013). Uracil DNA glycosylase initiates degradation of HIV-1 cDNA containing misincorporated dUTP and prevents viral integration. Proc Natl Acad Sci U S A, 110(6), E448-57.
- Spivak AM, Salgado M, Rabi SA, OConnell KA, Blankson JN (2011). Circulating monocytes are not a major reservoir of HIV-1 in elite suppressors. J Virol, 85(19), 10399-403.
- Gaillard S, Dinoso JB, Marsh JA, DeZern AE, OConnell KA, Spivak AM, Alwood K, Durand CM, Ambinder RF, Blankson JN (2011). Sustained elite suppression of replication competent HIV-1 in a patient treated with rituximab based chemotherapy. J Clin Virol, 51(3), 195-8.
- Spivak AM, Rabi SA, McMahon MA, Shan L, Sedaghat AR, Wilke CO, Siliciano RF (2011). Short communication: dynamic constraints on the second phase compartment of HIV-infected cells. AIDS Res Hum Retroviruses, 27(7), 759-61.
- Pradilla G, Nagahama Y, Spivak AM, Bydon A, Rigamonti D (2010). Spinal epidural abscess: current diagnosis and management. Curr Infect Dis Rep, 12(6), 484-91.
- Spivak AM, Brennan TP, OConnell KA, Sydnor E, Williams TM, Siliciano RF, Gallant JE, Blankson JN (2010). A case of seronegative HIV-1 infection. J Infect Dis, 201(3), 341-5.
Review
Case Report
- Szaniawski MA, Spivak AM (2019). Recurrent Paenibacillus infection. Oxf Med Case Reports, 2019(5), omz034.
- Johnson RA, Spivak AM (2017). Lues Maligna. Open Forum Infect Dis, 4(3), ofx139.
- Rachakonda T, Kendall B, Spivak AM, Boltax J (2017). Pleural Effusion Caused by Bacillus Calmette-Guérin Immunotherapy for Bladder Cancer. Open Forum Infect Dis, 4(3), ofx126.